Avi-Lution R is a defined, patented, synbiotic product containing Saccharomyces cerevisiae, Enterococcus faecium, and Bacillus spp. Broiler chickens (n = 1,250) were experimentally treated as uninoculated controls (uCon), inoculated controls (iCon) with Clostridium perfringens, or inoculated and treated with bacitracin methylene disalicylate (BMD) at 55 mg/kg as an infected/treated control or Avi-Lution R at 1.0 (AvL1) or 2.0 (AvL2) g/kg in feed for 42 d. Each treatment was applied to 10 replicate pens of 25 straightrun, newly hatched chicks. Pens treated with AvL1, AvL2, or BMD showed improved growth, feed efficiency, or mortality from necrotic enteritis compared with iCon pens at d 14, 28, and 42. No differences in these measurements, however, were observed between pens treated with AvL1 and AvL2, which suggests that Avi-Lution R was effective at 1.0 g/kg in feed. Despite improved performance, BMD, AvL1, and AvL2 treatments did not decrease the severity of intestinal lesion scores through 42 d of age compared with the infected control. These results demonstrate that Avi-Lution R improved growth performance and feed conversion rates in broilers challenged with Clostridium perfringens despite no difference in severity of intestinal lesion scores.
INTRODUCTION
Avi-Lution R is a patented synbiotic product containing live, proprietary strains of Saccharomyces cerevisiae, Enterococcus faecium, Bacillus subtilis, and Bacillus licheniformis, as well as β-glucans, mannan-oligosaccharides, and fructo-oligosaccharides. The product has been commercially available for use in poultry diets for over 16 years and has since been widely incorporated into broiler, turkey, and layer rations. The Avi-Lution R formula is based on the hypothesis of competitive exclusion, which states that the densities of competing species are defined by a common limiting resource (Hardin, 1960; Armstrong and McGehee, 1980) . Prebiotic strategies designed to promote competitive exclusion of enteric pathogens have been explored and validated, and include dietary supplementation of yeast cell wall preparations (MoralesLopez et al., 2009; Ganan et al., 2012) and live yeast (Kung et al., 1997; Gao et al., 2008) , which are components of Avi-Lution R . In addition, numerous lactic acid producing bacteria, including strains of Lactobacillus, Pediococcus, and Enterococcus (Brashears et al., 2003; Franz et al., 2011) have been hypothesized as candidates that promote intestinal health through a competitive exclusion mechanism.
We desired to document the effects of Avi-Lution R on growth performance and severity of infection in broiler chickens challenged with Clostridium perfringens. As briefly reviewed by Wade et al. (2016) , C. perfringens is a Gram-positive bacterium that is highly prevalent in the enteric ecosystem and which can cause necrotic enteritis (NE) in avian species. Although AviLution R has been extensively utilized in poultry diets, no peer reviewed study has ever documented the effects of this product on broiler performance during a controlled C. perfringens challenge. The present study therefore included 5 treatment groups including an uninfected group, infected control group, 2 treatment groups supplemented with Avi-Lution R at a low or high dose, and a control group that was infected and supplemented with BMD-50 R as an infected/treated control. BMD-50 R is a feed additive that contains bacitracin methylene disalicylate and is indicated for the prevention of NE caused by Clostridium spp. The supplemental levels of Avi-Lution R that were utilized in this study were intended to represent feeding rates that are commonly utilized in broiler houses. Inclusion of these 2 doses of Avi-Lution R was intended for the determination of whether a performance effect could be titrated according to dosage level.
MATERIALS AND METHODS

Ethics Statement
Experimental procedures and conditions were designed and carried out in accordance with the Guide for the Care and Use of Agricultural Animals in Research and Teaching. The broiler feeding trial was performed at a commercial research facility (Virginia Diversified Research Corp, Harrisonburg, VA). All procedures were supervised by an attending veterinarian.
Animals, Conditions, and Diets
Straight-run, newly hatched male Cobb 500 broiler chicks (n = 1,250) were obtained on d 0 as 5 stacks of 5 hatchery crates. Five healthy chicks from each of the 5 stacks were placed into a single weighing crate representing 1 of 50 study pens, such that each floorpen contained 25 chicks. No lame or diminished-vigor chicks were utilized, as excess chicks were available for selection. Each pen contained a single water fountain (Plasson, Israel) and a single 20.4 kg capacity feed tube. The dimensions of each pen, without consideration of equipment, provided an initial stocking density of approximately 0.072 m 2 per bird with approximate pen dimensions of 1.5 × 1.2 m. Birds were started on new wood shavings, but were exposed on d 4 to used litter sourced from healthy chickens not exposed to dietary enzymes or direct-fed microorganisms. Historically, broilers reared in the house from which litter was sourced were found to develop lesions of Eimeria acervulina. The addition of used litter to floor pens was thus intended to standardize exposure to enteric microorganisms, including Eimeria species (Chapman, 1999) . Used litter was placed on top of new shavings in a coned fashion so that all birds were exposed at the same time. Chicks also were vaccinated on d 4 with Coccivac-D2 R (Intervet, MSD Animal Health, Madison, NJ). All pens were located in the same building and continuous lighting as a stressful condition was provided through the duration of the study. All pens were checked at least daily for the availability of feed and water, and brooder (heater) was controlled for attainment of desired temperature.
Starter [d 0-14; 3,009 kcal metabolizable energy (ME)/kg, 20.83% crude protein (CP)], finisher (d 15-28; 3,073 kcal ME/kg, 18.09% CP), and withdrawal (d 29-42; 3135 kcal ME/kg, 16.06% CP) diets were prepared from proprietary, batch basal diets obtained from an integrated producer. Feed ingredients included corn, soybean meal, distiller's dried grains, and meat and bone meal, but a coccidiostat was not utilized. Basal diets were supplemented with BMD-50 R (bacitracin methylene disalicylate; Zoetis Products, Chicago Heights, IL) or with Avi-Lution R (Agri-King, Inc., Fulton, IL), as described below. All feeds were mixed and pelleted at the site of broiler production (Virginia Diversified Research Corp.) and samples of the study feeds were sent to a commercial feed analysis laboratory for verification of ration specifications (Analab, Agri-King, Inc.). Each broiler pen was weighed on d 0, 14, 28, and 42, and the mean bird weight per pen was calculated.
Weights were recorded for all feed delivered to pens, and remaining feed weights were recorded when birds were weighed.
Pen numbers were randomly assigned to 10 replicate blocks of 5 pens each in a modified randomized complete block design. Each pen per block corresponded with one of 5 treatments: uninoculated control (uCon); inoculated control (iCon); inoculated, BMD-50 R at 55 mg/kg in feed (BMD); inoculated, Avi-Lution R at 1.0 g/kg in feed (AvL1), infected, Avi-Lution R at 2.0 g/kg in feed (AvL2). Pens with uCon broilers were all located on one end of the broiler house to minimize cross-inoculation from pathogen-infected groups.
Clostridia Challenge System
Birds of iCon, BMD, AvL1, and AvL2 groups were inoculated with 2 beta-hemolytic strains of Clostridium perfringens on d 11, 12, and 13. C. perfringens clinical isolates designated as #6 and #7 were previously isolated from intestinal tracts originating from a commercial broiler operation experiencing symptoms of necrotic enteritis. C. perfringens isolates were identified by selective culture on Difco TM SFP agar base (Becton, Dickinson and Co., Franklin Lakes, NJ) as black H 2 S producing colonies. Successive plating on sheep blood agar revealed 7 Clostridium isolates that were beta-hemolytic. These isolates were previously titrated for pathogenicity upon reinfection into healthy broilers (data not shown) and isolates 6 and 7 were selected for use in the present experimental challenge.
Experimental inoculum of mixed C. perfringens isolates 6 and 7 was prepared in sterile meat broth to a concentration of approximately 10 12 cfu/mL. Following a 4 h feed fast and 1 h water fast, each bird in the iCon, BMD, AvL1, and AvL2 groups was orally gavaged with 2 mL of inoculation broth, and then feed and water were restored to each pen. The systematic restriction and reintroduction of feed and water was intended to standardize the rate of feed passage in the gastrointestinal tract after inoculation.
Bacitracin Sensitivity of C. perfringens Isolates
C. perfringens clinical isolates 6 and 7 were plated on Difco TM SFP agar (supplemented with Egg Yolk Enrichment 50% and Polymixin B sulfate) and incubated anaerobically at 37
• C for approximately 18 h. A single 6 mm bacitracin disc with potency of 10 IU (BBL TM Sensi-Disc TM Antimicrobial Susceptibility Test Discs, Becton, Dickinson, and Co.) was placed on the center of each plate. The zone of inhibition diameter was measured to the nearest 1.0 mm to classify isolates as susceptible (≥13 mm), intermediate (9-12 mm), or resistant (≤8 mm) according to manufacturer's specifications.
Performance Metrics
Pen and feed weights were collected on d 0, 14, 28, and 42. Mortality was also observed throughout the study as a percentage for each pen. Cause of death was determined for each mortality, so mortality from necrotic enteritis is reported as well as total mortality. Mortality-adjusted feed efficiency was calculated as total feed consumed per total gain, including weight of dead birds, for the pen. These data were analyzed for main effects of treatment and block by one-way ANOVA with Levene's test for homogeneity of variance and Welch's test for mean differences (Statistix 10, Analytical Software, Tallahassee, FL). Where F < 0.1, a post-hoc Tukey-adjusted LSD test with α of 0.05 was used to separate means. If the F-value failed to justify separation of means and the assumption of equal variance was not met, Welch's test (P < 0.1) governed the LSD test.
Necropsy, Necrotic Enteritis Lesion Scores, and Biological Samples
The carcasses of any birds that died during the experiment were necropsied to determine the probable cause of death. In addition, 3 birds from each pen were randomly caught and euthanized by cervical dislocation on d 14 and 42. Intestines were examined and scored blindly by a veterinarian for necrotic enteritis lesions based on a 0 to 3 scoring system similar to that described by Cravens et al. (2013) , where 0 = normal, 1 = flaccid or thinning tract with ≤2 necrotic areas, 2 = > 2 necrotic areas, and 3 = ubiquitously lesioned intestinal tissue. The attending veterinarian noted that some tracts classified as 3 could be characterized by a "Turkish towel" appearance, whereas some others were observably smooth, which was presumably caused by sloughing of the necrotic mucosa. The differential appearance of ubiquitously lesioned tissue classified as 3 did not affect scoring for statistical purposes. Care was taken to differentiate lesions associated with E. acervulina from other necrotic enteritic lesions and to exclude the former from statistical analysis. All animals that died were incinerated, and all animals remaining at the end of the trial were euthanized, incinerated, and buried. Lesion scores were ranked and analyzed by the KruskallWallis one-way nonparametric ANOVA (Statistix) with main effects of treatment and block. Where P < 0.05 (beta approximation; Meyer and Seaman, 2013) , mean rank was separated by Dunn's pairwise comparison test with α of 0.05. Mean rank and mean lesion score are both reported. 
RESULTS
Performance
Body weights (BW), cumulative mortality-adjusted feed conversion rate (MAFCR) and cumulative mortality were recorded at d 14, 28, and 42 (Table 1) . Birds were challenged with C. perfringens daily during d 11-13, so these dates correspond with approximately +1, +15, and +29 d post-challenge. At d 14, BW was not affected by treatment. Mortality-adjusted FCR, however, was lower (more efficient) for uCon (1.320 ± 0.017) and BMD (1.301 ± 0.015) than iCon pens (1.361 ± 0.014), and still lower in AvL1 (1.219 ± 0.009) and AvL2 pens (1.246 ± 0.009). Total mortality percentage was not different between uCon and iCon pens, but was significantly greater in AvL1 pens compared with iCon and BMD. No incidences of mortality observed from d 0-14 were associated with NE, whereas 11 of 16 mortalities were associated with pathogenesis in the air sac, and the other 5 were of undetermined cause. Greater total mortality in AvL1 pens during d 0-14 may perhaps be attributed to type I statistical error, as mortality was not different from controls in the AvL2 pens.
By d 28, symptoms of C. perfringens challenge were apparent in all metrics. Pens of the iCon group presented with 8.40 ± 0.93% cumulative mortality from NE, which was greater than all other groups, as well as decreased bodyweight and greater MAFCR. Mortality from NE was similar among uCon, BMD and AvL2 pens at d 28, whereas mortality in AvL1 was greater than in uCon and BMD pens. Bodyweight and MAFCR were similar among uCon and infected/treated groups at d 28 such that neither BW, MAFCR, nor mortality were statistically titratable at d 28 according to AvL dosage level. Final performance measurements were collected at d 42. Body weights of uCon pens (2.469 ± 0.042 kg) were statistically greater than those of iCon pens (2.217 ± 0.029 kg), whereas BW of iCon and BMD (2.230 ± 0.030 kg) pens were statistically similar. Body weights of AvL1 and AvL2 pens (2.368 ± 0.039 and 2.366 ± 0.39 kg, respectively) were statistically greater than iCon pens and similar with uCon, but BW of AvL2 pens were not different than BMD. Mortality-adjusted FCR was also lowest (most efficient; P < 0.05) for uCon (1.754 ± 0.017) and greatest (least efficient) for iCon pens (2.030 ± 0.024), whereas MAFCR was improved in infected/treated groups compared with iCon pens. Among treated groups, MAFCR was similar between BMD (1.920 ± 0.024) and AvL1 (1.865 ± 0.017), and between AvL1 and AvL2 (1.847 ± 0.018), but lower (more efficient) for AvL2 than for BMD pens. Cumulative NE-associated mortality was greater in iCon pens (9.20 ± 1.04%) than in other treatment groups, whereas NE-associated mortality was similar among infected/treated and uCon pens. Mortality not associated with NE was largely attributed to cardiac injury (56 of 288 mortalities), especially during the finisher period where this diagnosis accounted for approximately 64% of mortalities. Broilers in BMD pens exhibited lower total mortality than did birds of uCon and AvL1 pens, whereas mortality in AvL2 pens was similar with uCon and infected/treated groups.
Necrotic Enteritis Lesion Scores
Necrotic enteritis lesion scores (Table 2) were assessed in 3 randomly selected birds from each pen on d 14 and 42. Mean rank score at d 14 was significantly greater (P < 0.05) for iCon than for uCon pens, but infected/treated pens were not different from other groups. Scores in infected groups indicate that extensive lesioning of tissue was observed by d 14. By d 42, the mean lesion score for uCon pens was 1.43 ± 0.21 and mean scores for infected pens were all greater than 2.0, which indicates that C. perfringens challenge was generally persistent throughout the study. Mean rank was greater in AvL2 than in uCon, but not different among other infected/treated groups. This finding, along with 2 NE-associated mortalities in uCon broilers during the finisher period, reveals that symptoms of NE were observable even in uCon broilers at d 42 despite significantly improved performance over infected groups. This result is likely the outcome of utilizing the same airspace to house uCon and infected groups despite our best efforts to segregate pens.
Bacitracin Sensitivity in C. perfringens Isolates
Because BMD-treatment failed to decrease severity of C. perfringens-induced necrotic lesions or improve final growth performance compared with iCon pens, clinical isolates 6 and 7 were plated with a bacitracin disk to determine sensitivity. The zones of inhibition measured < 8 mm (bacitracin resistant) and approximately 16 mm (bacitracin sensitive) for isolates 6 and 7, respectively.
DISCUSSION
The primary objective of this study was to test whether Avi-Lution R improved broiler performance during challenge with Clostridium perfringens. In addition to primary (uninoculated) and secondary (inoculated) control treatments, treatment with BMD-50 R (supplemented at 55 mg/kg in feed) was utilized as a tertiary control to demonstrate the effect of a commercially available product with an indication from the Food and Drug Administration for treatment of necrotic enteritis from Clostridium species. The utilization of 3 control treatments was cumulatively effective despite limitations to all of these groups.
Broilers that were sampled from the uninoculated control group did present necrotic-enteritic lesions at d 42 and thus could not truly be regarded as uninfected. This result is not altogether unexpected, as these control broilers were subject to similar conditions to those of inoculated groups including exposure to used litter. We observed significant differences, however, in BW, MAFCR, and mortality at 28 and 42 d of age between uCon and iCon groups, which collectively demonstrate that the infected control group was quantifiably affected by inoculation with C. perfringens. In our opinion, the quantifiable effects of inoculation are sufficient to defend that the basal conditions applied to all pens were not confounding to the cumulative results of BW, MAFCR, and NE-associated mortality.
Treatment with BMD improved mortality and MAFCR at d 28 and d 42 compared with iCon, whereas BW was only different between these groups at d 28. We expected that BMD treatment would also decrease lesion scores, but this hypothesis was not demonstrated by our data. (We subsequently determined via conventional microbiological methods that one of the inoculous C. perfringens strains was resistant to bacitracin.) In light of isolate 6 demonstrating bacitracin resistance, we expect that growth performance of the BMD group could have been improved by utilizing only bacitracinsensitive isolates.
Despite the limitations of each control, we have demonstrated a performance challenge caused by the oral inoculation of C. perfringens that was partly ameliorated by BMD. The BW and MAFCR values associated with this challenge are quite contemporary among the body of necrotic enteritis literature as the broilers herein maintained similar feed efficiency to that reported by Józefiak et al. (2014) through 28 d, and similar weight gain to that reported by Tian et al. (2016) through 42 d of age. The effects of supplemental AviLution R during C. perfringens challenge have not previously been documented in either historical or contemporary peer-reviewed literature and thus represent new information. The data in Tables 1 and 2 demonstrate that although Avi-Lution R did not fully mitigate C. perfringens challenge at either 1.0 or 2.0 g/kg in feed, supplementation of the product did significantly improve broiler performance when compared with the inoculated control. Specifically, Avi-Lution R did not decrease severity of necrotic enteritis lesions, but decreased NE-associated mortality through 42 d and improved final BW and MAFCR.
A secondary objective of the present work was to describe any titratable result from supplementing AviLution R at 1.0 or 2.0 g/kg in feed during C. perfringens challenge. No statistical differences in growth performance or mortality were observed between the 2 dosage levels, which indicates that the effects of AviLution R during necrotic enteritis may be saturated at the 1.0 g/kg dose. With 25 broilers per floor pen, the experimental unit (pen) benefits from biological replication, so adequate statistical power is readily achieved for measures of growth performance and feed efficiency. Because of the binary nature of mortality, however, our analysis of this metric was perhaps under powered, despite the detection of significant differences among groups that include the infected control. Conclusions regarding mortality should thus be considered with great caution concerning both type I and II statistical error.
Although the combination of ingredients that comprises Avi-Lution R has not been previously tested for efficacy in a NE model, some related research has been reported that supports the hypothesis that AviLution R should be effective. Derivatives of Saccharomyces cerevisiae have been shown to improve avian intestinal health during coccidian challenge (Lensing et al., 2012) , whereas Hofacre et al. (2003) documented beneficial effects of a defined lactic acid bacterial (LAB) probiotic culture administered at d 1 of age followed by supplementation of mannanoligosaccharides in feed during C. perfringens challenge. Mannan-oligosaccharides are not homogenous, but have been shown to stimulate lymphocyte-mediated immunity in both avians and mammals (Swanson et al., 2002; Shashidhara and Devegowda, 2003) . Similarly, LAB are a diverse group of organisms that derive from multiple families within order Lactobacillales. Avi-Lution R includes only one strain of Enterococcus faecium, whereas much of the documented research concerning LAB has utilized strains of genus Lactobacillus or mixed cultures. Examples include a report by Aliakbarpour et al. (2012) where growth performance and intestinal morphology were improved by supplementation of LAB, Bacillus subtilis, or mixed cultures, as well as a more recent study by Olnood et al. (2015) , which documented increased anaerobic bacterial density in ileal and cecal contents that was concomitant with increased small intestinal weights. Even by this incomplete review of literature pertaining to treatment of enteric C. perfringens infections with antibiotic alternatives, we assert that our results are not completely without precedent.
Having identified that growth performance in broilers was improved by supplementation of Avi-Lution R during C. perfringens challenge, the mechanism of this effect remains to be reported. Samples of jejunal and cecal contents from broilers at d 42 of age have been the subjects of further scrutiny for metabolic evidence of competitive exclusion, which is to be reported separately. Briefly, we suspect that improved growth performance and MAFCR in AvL1 and AvL2 broilers may be tied to the efficient digestion and absorption of dietary nutrients, so we intend to report on concentrations of the organic acids as signatures of microbial metabolism in the intestine. Indeed, species of genus Clostridium are generally regarded as producers of butyric acid (Ishimoto et al., 1974) via their fermentation, whereas strains of Enterococcus faecium produce lactic acid (Hyrslova et al., 2016) . Altered fermentation of 3-carbon derivatives of glucose such as lactate or propionate, compared with derivatives of 2-carbon metabolism, such as acetate or butyrate, are not unprecedented during C. perfringens challenge (Wu et al., 2014) , so the ecology of this fermentation is presently being studied.
We conclude from the data presented herein only that inoculation of broilers with C. perfringens caused a pathogenic challenge that was readily quantified by decreased body weight, greater MAFCR, and greater mortality associated with necrotic enteritis. Avi-Lution R supplemented at 1.0 g/kg in feed significantly increased body weights, decreased MAFCR, and decreased NEassociated mortality, but did not affect lesion scores. No statistical improvement to performance was observed by supplementing Avi-Lution R at 2.0 g/kg in feed compared with 1.0 g/kg. The mechanism by which AviLution R improved broiler performance remains to be reported.
